Filing Flows › AbCellera Biologics (ABCL) › Q2 2026 › vs Q2 2025
AbCellera Biologics (ABCL) Q2 2026 vs Q2 2025 (year over year)
AbCellera Biologics's revenue fell $13.0M (-76%) from $17.1M in Q2 2025 to $4.0M in Q2 2026. The biggest changes: Licensing and royalty revenue −$10.3M (-99%); Research fees −$2.7M (-41%).
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 587.4% | -267.9% | +855.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Research fees | $3.9M | $6.6M | −$2.7M | -41% |
| Licensing and royalty revenue | $149K | $10.4M | −$10.3M | -99% |
| Revenue | $4.0M | $17.1M | −$13.0M | -76% |
| Other income, net | $3.8M | $13.2M | −$9.4M | -71% |
| Income tax benefit | $3.5M | $1.6M | $1.9M | +119% |
| Net loss | $55.4M | $34.7M | $20.7M | +60% |
| Costs & expenses | $66.8M | $66.7M | $158K | +0.2% |
| Operating costs | $66.8M | $66.7M | $158K | +0.2% |
| Research & development | $46.0M | $39.2M | $6.8M | +17% |
| Other operating costs | $7.0M | $5.5M | $1.5M | +28% |
| Operating cash sources | $81.3M | $2.3M | $79.0M | 35× |
| Depreciation & amortization | $7.0M | $5.5M | $1.5M | +28% |
| Share-based compensation | $12.3M | $14.2M | −$1.9M | -14% |
| Working capital & other | $62.1M | −$17.4M | $79.4M | — |
| Net loss absorbed | $55.4M | $34.7M | $20.7M | +60% |
| Operating cash flow | $25.9M | −$32.4M | $58.3M | — |
| Free cash flow (OCF − capex) | $23.8M | −$45.8M | $69.6M | — |
| Capital expenditures | $2.1M | $13.4M | −$11.2M | -84% |
Questions
How much did AbCellera Biologics's revenue grow year over year in Q2 2026?
AbCellera Biologics's revenue fell $13.0M (-76%) from $17.1M in Q2 2025 to $4.0M in Q2 2026.
What drove AbCellera Biologics's revenue change in Q2 2026?
Licensing and royalty revenue −$10.3M (-99%); Research fees −$2.7M (-41%).